TY  - GEN
N2  - Non-small cell lung cancer (NSCLC) accounts for one in five of all cancer deaths worldwide. Most patients are diagnosed at advanced stages, resulting in a 5-year survival rate of less than 20%. Recently, immune checkpoint inhibitors (ICIs) for PD-L1 and PD-1 have received FDA approval for the treatment of NSCLC. However, only a small subset of patients (15-20%) respond to ICIs, and many of these responders eventually relapse. Doxorubicin (DOX) is an FDA-approved chemotherapeutic used in treating many cancers, including lung cancer. However, it has dose-dependent toxicity and patients develop resistance to DOX over time.
DO  - 10.6083/bpxhc43646
DO  - doi
AB  - Non-small cell lung cancer (NSCLC) accounts for one in five of all cancer deaths worldwide. Most patients are diagnosed at advanced stages, resulting in a 5-year survival rate of less than 20%. Recently, immune checkpoint inhibitors (ICIs) for PD-L1 and PD-1 have received FDA approval for the treatment of NSCLC. However, only a small subset of patients (15-20%) respond to ICIs, and many of these responders eventually relapse. Doxorubicin (DOX) is an FDA-approved chemotherapeutic used in treating many cancers, including lung cancer. However, it has dose-dependent toxicity and patients develop resistance to DOX over time.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
T1  - Nanoparticles co-delivering doxorubicin & pd-l1 inhibitor to induce immunogenic cell death and enhance anti-cancer immune response in lung cancer
DA  - 2024
AU  - Kumar, Pramod
AU  - Wallstrum, Alyssa
AU  - Reda, Moataz
AU  - Wang, Ruijie
AU  - Ngamcherdtrakul, Worapol
AU  - Yantasee, Wassana
L1  - https://digitalcollections.ohsu.edu/record/43646/files/ResearchWeek.2024.Kumar.Pramod.pdf
PB  - Oregon Health and Science University
LA  - eng
PY  - 2024
ID  - 43646
L4  - https://digitalcollections.ohsu.edu/record/43646/files/ResearchWeek.2024.Kumar.Pramod.pdf
KW  - Immunogenic Cell Death
KW  - B7-H1 Antigen
KW  - Doxorubicin
KW  - Lung Neoplasms
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Immune Checkpoint Inhibitors
KW  - PD-L1
KW  - lung cancer
TI  - Nanoparticles co-delivering doxorubicin & pd-l1 inhibitor to induce immunogenic cell death and enhance anti-cancer immune response in lung cancer
Y1  - 2024
L2  - https://digitalcollections.ohsu.edu/record/43646/files/ResearchWeek.2024.Kumar.Pramod.pdf
LK  - https://digitalcollections.ohsu.edu/record/43646/files/ResearchWeek.2024.Kumar.Pramod.pdf
UR  - https://digitalcollections.ohsu.edu/record/43646/files/ResearchWeek.2024.Kumar.Pramod.pdf
ER  -